Why Is Agenus (AGEN) Stock Down 55% Today?
Source: CI Photos / Shutterstock.com Agenus (NASDAQ:AGEN) stock is falling hard on Thursday after the clinical-stage biotechnology company provided results from a Phase 2 clinical trial of botensilimab and balstilimab as a colorectal cancer treatment. …